New treatment available for repeated occlusion of arteries

New treatment available for repeated occlusion of arteries
A new endovascular brachytherapy procedure using liquid beta-emitting rhenium-188 is safe and effective in preventing restenosis in people with long-segment femoropopliteal in-stent stenosis, according to research published in the August issue of the Journal of Endovascular Therapy.

(HealthDay)—A new endovascular brachytherapy (EVBT) procedure using liquid beta-emitting rhenium-188 (Re-188) is safe and effective in preventing restenosis in people with long-segment femoropopliteal in-stent stenosis (ISS), according to research published in the August issue of the Journal of Endovascular Therapy.

Martin Werner, M.D., of Park Hospital in Leipzig, Germany, and colleagues conducted a study of 90 consecutive patients with symptomatic ISS/occlusion of the femoropopliteal segment who underwent angioplasty followed by a new EVBT method that uses liquid beta-emitting Re-188.

The researchers found the primary patency to be 95.2 percent at six months (follow-up of 88 patients) and 79.8 percent at 12 months (follow-up of 82 patients). One case of early and two cases of late acute thrombotic occlusions occurred. Nine patients experienced ISS and 10 patients experienced reocclusion of the treated segment. Overall clinical status improved for 67.0 and 62.2 percent at six and 12 months, respectively.

"In this study, the treatment of femoral ISS with beta radiation was safe and effective," the authors write. "Angioplasty in combination with EVBT resulted in a favorable primary patency rate of almost 80 percent and clinical improvement after 12 months. Most patients had non-focal patterns of ISS (diffuse, proliferative, or total occlusion) and would have been expected to respond poorly to angioplasty alone."

More information: Abstract
Full Text
Editorial

add to favorites email to friend print save as pdf

Related Stories

Results of the REMEDEE trial reported at TCT 2011

Nov 11, 2011

A randomized comparison of a dual therapy stent – which combines low-dose sirolimus delivery from an abluminal biodegradable polymer matrix with a covalently bound anti-CD34 antibody layer – with a paclitaxel-eluting ...

Recommended for you

Gene variant raises risk for aortic tear and rupture

Apr 17, 2014

Researchers from Yale School of Medicine and Celera Diagnostics have confirmed the significance of a genetic variant that substantially increases the risk of a frequently fatal thoracic aortic dissection or full rupture. ...

Considerable variation in CT use in ischemic stroke

Apr 17, 2014

(HealthDay)—For patients with ischemic stroke there is considerable variation in the rates of high-intensity computed tomography (CT) use, according to a study published online April 8 in Circulation: Ca ...

Beating the clock for ischemic stroke sufferers

Apr 17, 2014

A ground-breaking computer technology raises hope for people struck by ischemic stroke, which is a very common kind of stroke accounting for over 80 per cent of overall stroke cases. Developed by research experts at The Hong ...

User comments